Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will complement commercial payload, linker and monoclonal antibodies services, enabling Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
Author's summary: Syngene International expands ADC development capabilities.
More News
- State begins distributing disaster aid to residents of Western Alaska, federal aid also approved
- SJHN Daily: Celebrini Named NHL First Star of the Week
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate | PharmExec
- It’s All About Dance Music as Dexter Community Band Kicks Off its 2025-26 Season - The Sun Times News
- Lightning place forward Mitchell Chaffee on waivers
- Frogs help Fred Hutch find the shape of small things
- WEEK 10 SEMOBALL TOP 10: Dexter back up, St. Vincent sneaks forward
- First Duel Night Abyss Figure Is Based on Psyche
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids